The role of Serpina3n in the reversal effect of ATRA on dexamethasone-inhibited osteogenic differentiation in mesenchymal stem cells.

Hai-Tao JiangRui DengYan DengMao NieYi-Xuan DengHong-Hong LuoYuan-Yuan YangNa NiCheng-Cheng RanZhong-Liang Deng

Published in: Stem cell research & therapy (2021)

ATRA can reverse DEX-inhibited osteogenic differentiation both in vitro and in vivo, which may be closely related to the downregulation of DEX-promoted Serpina3n. Hence, ATRA may be viewed as a novel therapeutic agent, and Serpina3n may act as a new target for GIOP.

Keyphrases

mesenchymal stem cells
umbilical cord
bone marrow
cell therapy
cell proliferation
signaling pathway
low dose
high dose
stem cells